• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Vivia Biotech closes second round of funding for $9.4 million

Vivia Biotech closes second round of funding for $9.4 million

April 16, 2012
CenterWatch Staff

Vivia Biotech, a Spanish company focused on hematologic cancers, has successfully closed its second financing round of $9.4 million.

“This transaction is a milestone that sends a clear message to the market to opt for innovative projects with real added value, especially for biotech SMEs within the actual economic and financial situation that we are living in Spain,” said Andres Ballesteros, CEO of Vivia Biotech. “Closing a deal of this volume endorses Vivia’s bet for innovation, and demonstrates the company’s potential and the capacity to attract funding when there is a solid project behind.”

The operation includes funding of $7.8 million in participatory loans by the Society for the Promotion and Economic Restructuring in Andalusia (SAU) on behalf of the Multiinstrument JEREMIE Fund and an additional equity investment of $1.6 million by Bioanalítica Inversiones.

The new injection of capital will finance the commercialization of Vivia’s personalized medicine test for hematologic cancers. It will also enable the continued development of the company’s two main drug candidates, one for the treatment of non-Hodgkin Lymphoma (expected to begin clinical trials in patients later this year) and a second high-potential candidate for diabetes. Vivia is in negotiations with pharmaceutical companies for potential collaborations to further the development of both drug
candidates.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing